These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 14962580)

  • 41. FDA pressure?
    Appleton BL
    Nature; 1990 Mar; 344(6262):99. PubMed ID: 2308647
    [No Abstract]   [Full Text] [Related]  

  • 42. [Crystallization and solid state properties of molecules of pharmaceutical interest].
    Bauer M
    Ann Pharm Fr; 2002 May; 60(3):152-60. PubMed ID: 12050594
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Failures of the therapeutic chain as a cause of drug ineffectiveness.
    Figueras A; Laporte JR
    BMJ; 2003 Apr; 326(7395):895-6. PubMed ID: 12714454
    [No Abstract]   [Full Text] [Related]  

  • 44. Regulatory observations in bioanalytical determinations.
    Viswanathan CT
    Bioanalysis; 2010 Jul; 2(7):1325-9. PubMed ID: 21083243
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 46. Drug hydrate systems and dehydration processes studied by terahertz pulsed spectroscopy.
    Zeitler JA; Kogermann K; Rantanen J; Rades T; Taday PF; Pepper M; Aaltonen J; Strachan CJ
    Int J Pharm; 2007 Apr; 334(1-2):78-84. PubMed ID: 17129691
    [TBL] [Abstract][Full Text] [Related]  

  • 47. International Conference on Harmonisation; guidance on Q9 Quality Risk Management; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Jun; 71(106):32105-6. PubMed ID: 16795933
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Polymorphism in drug design and delivery.
    Bernstein J
    Prog Clin Biol Res; 1989; 289():203-15. PubMed ID: 2657749
    [No Abstract]   [Full Text] [Related]  

  • 49. Keeping watch on drug quality.
    Furman WB
    FDA Consum; 1975 Oct; 9(8):18-23. PubMed ID: 10316632
    [No Abstract]   [Full Text] [Related]  

  • 50. Hot drugs 2004.
    Nat Rev Drug Discov; 2004 Jul; Suppl():S3-40. PubMed ID: 15270027
    [No Abstract]   [Full Text] [Related]  

  • 51. Is the bioanalytical community ready to revise the use of certain validation concepts and nomenclature?
    Olsson AO; Liljeblad M; Nilsson LB; Silvester S
    Bioanalysis; 2012 Jul; 4(14):1705-8. PubMed ID: 22877214
    [No Abstract]   [Full Text] [Related]  

  • 52. Issues in bringing new drugs to the market.
    Tracey WR
    Science; 2005 Dec; 310(5753):1425-6; author reply 1425-6. PubMed ID: 16329172
    [No Abstract]   [Full Text] [Related]  

  • 53. Best practices for the development, scale-up, and post-approval change control of IR and MR dosage forms in the current quality-by-design paradigm.
    Van Buskirk GA; Asotra S; Balducci C; Basu P; DiDonato G; Dorantes A; Eickhoff WM; Ghosh T; González MA; Henry T; Howard M; Kamm J; Laurenz S; MacKenzie R; Mannion R; Noonan PK; Ocheltree T; Pai U; Poska RP; Putnam ML; Raghavan RR; Ruegger C; Sánchez E; Shah VP; Shao ZJ; Somma R; Tammara V; Thombre AG; Thompson B; Timko RJ; Upadrashta S; Vaithiyalingam S;
    AAPS PharmSciTech; 2014 Jun; 15(3):665-93. PubMed ID: 24578237
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Introduction to calibration curves in bioanalysis.
    Brewer E; Bollin E
    Bioanalysis; 2009 Oct; 1(7):1201-8. PubMed ID: 21083046
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Key factors in the rising cost of new drug discovery and development.
    Dickson M; Gagnon JP
    Nat Rev Drug Discov; 2004 May; 3(5):417-29. PubMed ID: 15136789
    [No Abstract]   [Full Text] [Related]  

  • 56. Comparison of the recovery spread in analytical development and routine quality control--based on the ICH quality guideline Q2B.
    Schepers U; El Deeb S; Ermer J; Wätzig H
    J Pharm Biomed Anal; 2007 Jan; 43(2):708-10. PubMed ID: 16904281
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmaceutical postmarket review: fact or fiction?
    Schanz SJ
    Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391
    [No Abstract]   [Full Text] [Related]  

  • 58. The potential impact of usp general chapter <797> on procedures and requirements for the preparation of sterile radiopharmaceuticals.
    Hung JC
    J Nucl Med; 2004 Jun; 45(6):21N-6N. PubMed ID: 15181115
    [No Abstract]   [Full Text] [Related]  

  • 59. International Conference on Harmonisation; guidance on Q10 Pharmaceutical Quality System; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Apr; 74(66):15990-1. PubMed ID: 19507321
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Technical implications on the quality standard of new drugs].
    Uchiyama M
    Eisei Shikenjo Hokoku; 1995; (113):135-6. PubMed ID: 8717247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.